Cornell’s Research Serves the Region and Beyond

Alcyone LifeSciences Inc. CTL

R&D: Biopharmaceuticals

  • Products:
  • Microfabricated drug delivery systems

Alcyone LifeSciences Inc. addresses the unmet needs in treating chronic neuropathological conditions. For many neurologic conditions including brain tumor, hydrocephalus, epilepsy, and neurodegenerative disease, the current treatment modalities are sub-optimal. Alcyone is dedicated to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from these chronic conditions. For many neurologic conditions there are identified molecular targets, but the blood-brain barrier prevents drugs addressing those targets from precisely reaching diseased brain regions. Control and precision are fundamental needs in molecular therapy to the central nervous system. Alcyone LifeSciences has created a foundational technology with platform potential that can optimize molecular therapy to the brain and central nervous system.

Cornell Connection

The company's scientific founder is a Cornell professor of Chemical and Biomolecular Engineering, and Biomedical Engineering. The company's foundational technology is licensed from Cornell University.